secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001193125-22-222823
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics appoints Michael Vasconcelles to board; CMO Jeffrey Humphrey departs
--------------------------------------------------------------------------------

- Michael Vasconcelles, M.D. appointed to board, filling vacancy from Alexis Borisy not being reelected.
- Vasconcelles brings 30+ years in oncology; served as CMO at Flatiron Health and Unum Therapeutics.
- Chief Medical Officer Jeffrey Humphrey parted ways on August 15, 2022, not due to disagreement.
- Shawn Rose, M.D., Ph.D., appointed SVP and Head of Clinical Development effective immediately.
- Rose joined Magenta in February 2022; previously at Annexon, Janssen, and Bristol Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/0001193125-22-222823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312522222823/d390683d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-222823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer